Angiotensin II in Abdominal Aortic Aneurysm Models: Bridging Senescence and Vascular Remodeling

Introduction

Abdominal aortic aneurysm (AAA) presents a significant clinical challenge due to its asymptomatic progression and high mortality rate upon rupture. Understanding the molecular mechanisms underlying AAA formation and expansion is critical for developing early diagnostic methods and innovative interventions. One key experimental tool in cardiovascular research is Angiotensin II, an endogenous octapeptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) that serves as a potent vasopressor and GPCR agonist. Its capacity to induce vascular remodeling and inflammatory responses in preclinical models has made it indispensable for dissecting the hypertension mechanism and the complex pathophysiology of AAA.

Angiotensin II: Mechanistic Insights and Experimental Utility

Angiotensin II is synthesized as part of the renin-angiotensin-aldosterone system (RAAS), exerting powerful effects on vascular tone and fluid homeostasis. It binds to angiotensin receptors on vascular smooth muscle cells (VSMCs), triggering a cascade of signaling events: phospholipase C activation, generation of inositol trisphosphate (IP3), and subsequent IP3-dependent calcium release. These processes converge on protein kinase C (PKC) and other pathways, culminating in vasoconstriction, VSMC hypertrophy, and enhanced aldosterone secretion, which promotes renal sodium reabsorption and fluid retention.

In research settings, Angiotensin II is typically employed in vitro at nanomolar concentrations (e.g., 100 nM for 4 hours in VSMCs), where it elevates NADH/NADPH oxidase activity and induces oxidative stress. For in vivo experiments, especially in murine models, chronic infusion via subcutaneous minipumps (500–1000 ng/min/kg for 28 days) reliably triggers AAA formation, accompanied by medial thickening, extracellular matrix remodeling, and leukocyte infiltration—hallmarks of vascular injury and inflammation.

Connecting Angiotensin II-Induced AAA to Cellular Senescence: Emerging Paradigms

A novel dimension to AAA pathogenesis is the involvement of cellular senescence, particularly within vascular endothelial and smooth muscle compartments. Recent transcriptomic studies, such as the one by Zhang et al. (Journal of Cellular and Molecular Medicine, 2025), have identified differentially expressed senescence-related genes (DESRGs) that distinguish aneurysmal from healthy tissues. Notably, two hub genes—ETS1 and ITPR3—emerge as robust diagnostic biomarkers and are closely linked to the senescent phenotype in vascular cells.

The mechanistic interplay between Angiotensin II and cellular senescence is multifaceted. Angiotensin II, via sustained GPCR activation, can drive VSMC proliferation, phenotypic switching, and premature senescence. The upregulation of IP3 receptor isoforms (including ITPR3) in response to Angiotensin II-induced phospholipase C activation and calcium flux underscores direct molecular crosstalk between RAAS signaling and senescence pathways. Furthermore, Angiotensin II promotes a senescence-associated secretory phenotype (SASP), fostering a pro-inflammatory microenvironment that accelerates aneurysm development.

Experimental Protocols: Leveraging Angiotensin II for AAA and Senescence Research

For investigators aiming to model AAA or study vascular injury inflammatory responses, Angiotensin II offers reproducibility and translational relevance. Key considerations include:

• Peptide Preparation: Angiotensin II is soluble at ≥234.6 mg/mL in DMSO and ≥76.6 mg/mL in water. For biological assays, sterile water is preferred for stock solutions (>10 mM), which are stable at -80°C for several months.
• In Vitro Application: Exposure of VSMCs to 100 nM Angiotensin II for 4 hours reliably increases oxidative enzyme activity and mimics hypertrophic signaling, facilitating vascular smooth muscle cell hypertrophy research and mechanistic dissection of the angiotensin receptor signaling pathway.
• In Vivo Infusion: In C57BL/6J (apoE^–/–) mice, subcutaneous minipump delivery (500–1000 ng/min/kg) over 28 days induces AAA with characteristic vascular remodeling and resistance to dissection, making it a robust abdominal aortic aneurysm model.

These protocols enable direct interrogation of phospholipase C activation, IP3-dependent calcium release, and downstream pathways that orchestrate vascular remodeling, inflammation, and senescence.

Integrating Senescence Signatures: Diagnostic and Therapeutic Implications

The convergence of Angiotensin II-induced pathophysiology with cellular senescence gene signatures presents new opportunities for translational research. The study by Zhang et al. (2025) leveraged machine learning to identify 19 DESRGs from transcriptomic datasets, with ETS1 and ITPR3 validated as AAA biomarkers across human and murine samples. Elevated expression of ITPR3—encoding the type 3 IP3 receptor—highlights a mechanistic link to Angiotensin II-driven calcium signaling.

In addition, single-cell RNA sequencing data reveal that senescent endothelial cells accumulate in AAA lesions, expressing high levels of ETS1 and ITPR3. This suggests that Angiotensin II not only accelerates vascular remodeling but also amplifies senescence-associated changes, which may be targetable in future therapies. Monitoring these biomarkers could improve noninvasive AAA diagnostics and potentially refine patient stratification for early intervention.

Expanding the Research Landscape: Applications and Future Directions

The versatility of Angiotensin II extends beyond AAA modeling. Its role as a potent vasopressor and GPCR agonist has facilitated studies in hypertension mechanisms, cardiovascular remodeling investigation, and renal sodium reabsorption dynamics. Inflammatory responses induced by vascular injury, as well as the molecular underpinnings of VSMC hypertrophy, continue to be elucidated using Angiotensin II-based assays.

Emerging research avenues include combinatorial approaches that pair Angiotensin II infusion with genetic or pharmacological modulation of senescence pathways. This could clarify the causal contributions of DESRGs and inform the development of senolytic therapies aimed at attenuating AAA progression. Furthermore, the integration of high-throughput omics technologies and advanced imaging may enable more granular mapping of angiotensin receptor signaling pathway alterations in vivo.

Explicit Contrast with Existing Literature

While prior works such as "Angiotensin II: Unraveling GPCR Signaling in AAA Pathogenesis" have focused primarily on canonical signaling cascades and their roles in aneurysm formation, the present article uniquely synthesizes recent advances in senescence biology and biomarker discovery. By explicitly linking Angiotensin II-driven experimental models to the identification and validation of senescence-related diagnostic genes (such as ETS1 and ITPR3), this piece extends the research narrative to encompass translational applications in early AAA detection and therapeutic innovation. This integrative perspective addresses a critical knowledge gap and offers practical guidance for leveraging Angiotensin II in the context of emerging senescence paradigms.

Conclusion

The use of Angiotensin II as an experimental tool has been instrumental in advancing our understanding of vascular biology, particularly in the context of abdominal aortic aneurysm and its molecular drivers. The intersection of angiotensin receptor signaling, phospholipase C activation, IP3-dependent calcium release, and cellular senescence offers a fertile ground for discovery. As senescence-related biomarkers gain traction for AAA diagnosis and risk stratification, Angiotensin II-based models will remain at the forefront of cardiovascular research, bridging the gap between mechanistic insight and clinical application.